AN2 Therapeutics, Inc. (ANTX) Misses Q4 EPS by 7c

AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q4 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22).

For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.

You May Also Be Interested In

• The LGL Group (LGL) Misses Q2 EPS by 8c
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• Bitmine reports 5.82 million ETH holdings, $11.4B total assets